Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Endocrinology · Graves' Disease

Understanding Your Labs: The Path to Diagnosis

At a Glance

Graves' disease is confirmed by identifying specific immune system antibodies, primarily TRAb or TSI, alongside low TSH and elevated T3 and T4 hormones. Modern diagnosis often relies on these precise antibody blood tests rather than radioactive imaging to quickly and safely confirm the condition.

Understanding your lab results is one of the most empowering steps you can take in your Graves’ disease journey. While a diagnosis often begins with standard thyroid tests (TSH, T4, and T3), those only show that your thyroid is overactive—they don’t explain why [1]. To confirm Graves’ disease, doctors must look for the specific “fingerprints” of the immune system: the antibodies.

The Antibody Key: TRAb vs. TSI

In Graves’ disease, your immune system produces proteins called TSH Receptor Antibodies (TRAb) [2]. You may see two different terms on your lab report, and it helps to know the difference:

  • TRAb (TSH Receptor Antibody): This is an “umbrella” term. It measures any antibody that binds to the TSH receptor on your thyroid [3]. It is highly accurate for diagnosing Graves’ disease [4].
  • TSI (Thyroid-Stimulating Immunoglobulin): This is a more specific type of test. It doesn’t just look for the presence of antibodies; it measures those that specifically stimulate the thyroid to grow and produce hormone [5][6].

Stimulating vs. Blocking Antibodies

Not all antibodies act the same way. Most Graves’ patients have stimulating antibodies (TSI), which act like a “gas pedal,” forcing the thyroid into overdrive [7]. Rarely, a person may have blocking antibodies, which act like a “brake” and can actually cause an underactive thyroid (hypothyroidism) [8]. Some patients may even “switch” between these two, causing their thyroid levels to fluctuate unexpectedly [9].

Modern Diagnosis: The “TRAb-First” Approach

In the past, the standard way to diagnose Graves’ disease was a Radioactive Iodine Uptake (RAIU) scan, which involved swallowing a small amount of radioactive iodine to see how the gland absorbed it [10].

Current clinical evidence now favors a “TRAb-First” approach [11]. Because modern TRAb blood tests are so precise, they can often confirm Graves’ disease faster, more cheaply, and without the need for radiation [12][13]. A radioactive scan is typically reserved for cases where antibody tests are negative or unclear [14].

Ultrasound and the “Thyroid Inferno”

If your doctor ordered an ultrasound with Color Doppler, they are looking at the blood flow within the gland. A healthy thyroid has moderate blood flow, but a thyroid with Graves’ disease is often “hypervascular”—meaning it has an exceptionally high amount of blood flowing through it [15].

Radiologists sometimes use the dramatic term “thyroid inferno” to describe this appearance on the screen [16]. Do not let the name alarm you. Your thyroid is not actually burning, hot, or painful. It simply means that the blood flow looks very bright and intense on the computer screen, which is a strong indicator of an overactive gland [15].

Diagnostic Completeness Checklist

A thorough diagnostic report for Graves’ disease should ideally include:

  1. Low TSH Level: Usually near zero, showing the pituitary is trying to “shut off” the thyroid [1].
  2. Elevated Free T4 and Free T3: The actual hormones causing your symptoms [10].
  3. Positive TRAb or TSI: The evidence that the cause is autoimmune [17].
  4. Imaging Notes: Mentions of “increased vascularity” or a “diffuse” (all-over) pattern of activity [15][18].

Common questions in this guide

What is the difference between TRAb and TSI tests for Graves' disease?
TRAb is an umbrella term for any antibody that binds to the TSH receptor on your thyroid. TSI is a more specific test that measures only the antibodies that actively stimulate the thyroid to produce excess hormone.
Why is my TSH low but my T3 and T4 are high?
In Graves' disease, antibodies force your thyroid to produce high levels of T3 and T4 hormones. Your pituitary gland senses these high levels and drops your TSH near zero in an attempt to signal the thyroid to stop producing hormones.
What does a 'thyroid inferno' on my ultrasound mean?
The term 'thyroid inferno' is used by radiologists to describe intense, bright blood flow seen on a Color Doppler ultrasound. It simply means your thyroid is highly active and hypervascular, which is common in Graves' disease. It does not mean your thyroid is actually hot or burning.
Can taking biotin affect my Graves' disease lab results?
Yes, taking vitamins or supplements containing biotin within 72 hours of your blood draw can significantly skew thyroid lab results. Always tell your doctor about any supplements you are taking before having your thyroid levels checked.
Do I need a radioactive iodine scan to diagnose Graves' disease?
Not always. Many doctors now use a 'TRAb-first' approach, using precise blood tests to confirm the disease quickly and without radiation. A radioactive iodine scan is typically reserved for cases where antibody blood tests are negative or unclear.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What specific antibody tests did we run (TRAb or TSI), and were the results stimulating or blocking?
  2. 2.Why did you choose the 'TRAb-first' approach (or a radioactive scan) for my specific case?
  3. 3.If my ultrasound showed 'increased vascularity' or an 'inferno' pattern, what does that tell us about how active my disease is right now?
  4. 4.How might my antibody levels change over the next year, and will we re-test them before considering stopping medication?
  5. 5.Do any of my other lab results, like my liver enzymes or white blood cell count, affect which treatment we should start with?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Hyperthyroidism.

    McDermott MT

    Annals of internal medicine 2020; (172(7)):ITC49-ITC64 doi:10.7326/AITC202004070.

    PMID: 32252086
  2. 2

    Preoperative management in patients with Graves' disease.

    Piantanida E

    Gland surgery 2017; (6(5)):476-481 doi:10.21037/gs.2017.05.09.

    PMID: 29142837
  3. 3

    Graves Disease With Thyroid-Stimulating Hormone Receptor-Blocking Autoantibodies During Pregnancy.

    Decallonne B, Martens PJ, Van den Bruel A, et al.

    Annals of internal medicine 2020; (172(11)):767-769 doi:10.7326/L19-0818.

    PMID: 32203974
  4. 4

    Differentiation between Graves' disease and painless thyroiditis by diffusion-weighted imaging, thyroid iodine uptake, thyroid scintigraphy and serum parameters.

    Meng Z, Zhang G, Sun H, et al.

    Experimental and therapeutic medicine 2015; (9(6)):2165-2172 doi:10.3892/etm.2015.2430.

    PMID: 26136954
  5. 5

    Clinical diagnostic performance of a fully automated TSI immunoassay vs. that of an automated anti‑TSHR immunoassay for Graves' disease: a Chinese multicenter study.

    Cheng X, Chai X, Ma C, et al.

    Endocrine 2021; (71(1)):139-148 doi:10.1007/s12020-020-02386-2.

    PMID: 32562184
  6. 6

    Predictive Performance of 2 Immunoassays in Patients with Graves Disease Undergoing Radioiodine Therapy: Prospective Study.

    de Souza MVR, Sapienza MT, Brito LP, et al.

    Journal of the Endocrine Society 2025; (9(3)):bvaf016 doi:10.1210/jendso/bvaf016.

    PMID: 39935695
  7. 7

    Autoimmune Thyroid Diseases in Patients Treated with Alemtuzumab for Multiple Sclerosis: An Example of Selective Anti-TSH-Receptor Immune Response.

    Rotondi M, Molteni M, Leporati P, et al.

    Frontiers in endocrinology 2017; (8()):254 doi:10.3389/fendo.2017.00254.

    PMID: 29033895
  8. 8

    Alemtuzumab-Induced Autoimmune Thyroid Dysfunction.

    Ragavan S, Elhelw O, Majeed W, et al.

    Cureus 2022; (14(3)):e22751 doi:10.7759/cureus.22751.

    PMID: 35371892
  9. 9

    Alemtuzumab-Induced Thyroid Dysfunction Exhibits Distinctive Clinical and Immunological Features.

    Pariani N, Willis M, Muller I, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(8)):3010-3018 doi:10.1210/jc.2018-00359.

    PMID: 29878256
  10. 10

    SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves' disease after COVID-19.

    Mateu-Salat M, Urgell E, Chico A

    Journal of endocrinological investigation 2020; (43(10)):1527-1528 doi:10.1007/s40618-020-01366-7.

    PMID: 32686042
  11. 11

    A TRAb-First Diagnostic Strategy for Overt Hyperthyroidism: Diagnostic Performance and Implications for Reflex Testing.

    Petranović Ovčariček P, Campennì A, D'Aurizio F, et al.

    Journal of clinical medicine 2026; (15(2)) doi:10.3390/jcm15020445.

    PMID: 41598383
  12. 12

    TSH Receptor Antibody Test Utilization Patterns From a National Reference Laboratory: TRAb, TSI, or Both?

    Nelson HA, Doyle K, Straseski JA

    The Journal of clinical endocrinology and metabolism 2025; (111(1)):e92-e99 doi:10.1210/clinem/dgaf330.

    PMID: 40482060
  13. 13

    Performance of the Siemens' thyroid stimulating immunoglobulin assay in the diagnosis of hyperthyroidism: Prospective cohort study.

    Kline GA, Proctor DT, Moledina N, et al.

    Clinical biochemistry 2025; (137()):110938 doi:10.1016/j.clinbiochem.2025.110938.

    PMID: 40286898
  14. 14

    Evaluation of the role of thyroid scintigraphy in the differential diagnosis of thyrotoxicosis.

    Perdomo CM, García-Goñi M, Sancho L, et al.

    Clinical endocrinology 2021; (94(3)):466-472 doi:10.1111/cen.14308.

    PMID: 32767493
  15. 15

    Thyroid vascularization is an important ultrasonographic parameter in untreated Graves' disease patients.

    Vita R, Di Bari F, Perelli S, et al.

    Journal of clinical & translational endocrinology 2019; (15()):65-69 doi:10.1016/j.jcte.2019.01.001.

    PMID: 30792955
  16. 16

    Study of the Associations between Color Doppler Ultrasound Grading of Hyperthyroidism and Biochemical Data on Thyroid Function.

    Zhang L, Li J, Zhang S, et al.

    International journal of endocrinology 2022; (2022()):9743654 doi:10.1155/2022/9743654.

    PMID: 35942151
  17. 17

    TSH RECEPTOR ANTIBODIES: RELEVANCE & UTILITY.

    Kahaly GJ, Diana T, Olivo PD

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2020; (26(1)):97-106 doi:10.4158/EP-2019-0363.

    PMID: 32022598
  18. 18

    New-onset graves' disease after the initiation of nivolumab therapy for gastric cancer: a case report.

    Yamada H, Okajima F, Onda T, et al.

    BMC endocrine disorders 2020; (20(1)):132 doi:10.1186/s12902-020-00613-5.

    PMID: 32847555

This page explains Graves' disease diagnostic tests and lab results for educational purposes only. Always consult your endocrinologist or primary care physician to interpret your specific lab values and ultrasound reports.

Get notified when new evidence is published on Graves disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.